Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial. by Tagbor, Harry et al.
Tagbor, H; Antwi, GD; Acheampong, PR; Bart Plange, C; Chan-
dramohan, D; Cairns, M (2016) Seasonal malaria chemoprevention
in an area of extended seasonal transmission in Ashanti, Ghana:
an individually-randomised clinical trial. Tropical medicine & in-
ternational health , 21 (2). pp. 224-35. ISSN 1360-2276 DOI:
10.1111/tmi.12642
Downloaded from: http://researchonline.lshtm.ac.uk/2373852/
DOI: 10.1111/tmi.12642
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Seasonal malaria chemoprevention in an area of extended
seasonal transmission in Ashanti, Ghana: an individually
randomised clinical trial
Harry Tagbor1,2, Gifty Dufie Antwi2, Princess Ruhama Acheampong2, Constance Bart Plange3,
Daniel Chandramohan4 and Matthew Cairns5
1 School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
2 Centre for Global Health Research, Juaben, Ghana
3 National Malaria Control Programme, Ghana Health Service, Accra, Ghana
4 Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK
5 MRC Tropical Epidemiology Group, London School of hygiene and tropical medicine, London, UK
Abstract objective To investigate the effectiveness of seasonal malaria chemoprevention (SMC) and
community case management with long-acting artemisinin-based combination therapies (ACTs) for
the control of malaria in areas of extended seasonal malaria transmission.
method Individually randomised, placebo-controlled trial in the Ashanti Region of Ghana. A total
of 2400 children aged 3–59 months received either: (i) a short-acting ACT for case management of
malaria (artemether-lumefantrine, AL) plus placebo SMC, or (ii) a long-acting ACT
(dihydroartemisinin-piperaquine, DP) for case management plus placebo SMC or (iii) AL for case
management plus active SMC with sulphadoxine-pyrimethamine and amodiaquine. SMC or placebo
was delivered on five occasions during the rainy season. Malaria cases were managed by community
health workers, who used rapid diagnostic tests to confirm infection prior to treatment.
results The incidence of malaria was lower in children given SMC during the rainy season. Compared
to those given placebo SMC and AL for case management, the adjusted hazard ratio (aHR) was 0.62
(95% CI: 0.41, 0.93), P = 0.020 by intention to treat and 0.53 (95% CI: 0.29, 0.95), P = 0.033 among
children given five SMC courses. There were no major differences between groups given different ACTs
for case management (aHR DP vs. AL 1.18 (95% CI 0.83, 1.67), P = 0.356).
conclusion SMC may have an important public health impact in areas with a longer transmission
season, but further optimisation of SMC schedules is needed to maximise its impact in such settings.
keywords seasonal malaria chemoprevention, community case management, artemisinin-based
combination therapies, individually randomised, placebo-controlled trial, Ashanti, Ghana
Introduction
Seasonal malaria chemoprevention (SMC) is a highly
effective means to control malaria in areas with a short
rainy season, where a large proportion of the annual
malaria burden occurs within a few months of the year
[1]. SMC involves monthly administration of the long-act-
ing antimalarial drugs sulfadoxine-pyrimethamine and
amodiaquine (SP-AQ) to all children under five years of
age, regardless of whether or not they are infected, and is
a policy recommended by WHO for malaria control in the
Sahel and sub-Sahel regions of Africa [2]. To date, most
studies of SMC have taken place in areas with a short
rainy season [3–7], and current evidence suggests that, for
SMC to be appropriate, 60% of the total annual burden
of malaria should occur within 4 months of the year [8].
However, the basic approach used in SMC (monthly
‘cycles’ of SP-AQ during the period of highest risk) could
be adapted to cover a longer period of risk in areas where
malaria is transmitted for longer each year, and the bur-
den is spread more evenly over a longer period. There are
large highly populated areas of West Africa where SP and
AQ are still highly effective, and which have rainy seasons
ranging from 5 to 6 months in length [8, 9]. If SMC were
effective in such areas, this would substantially increase
the overall population that could be protected by SMC
and would help to reduce the large burden of malaria in
children in West Africa. To date, only two other studies
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have considered SMC given over a longer period: a study
in Hohoe, Ghana, where artesunate-amodiaquine was
given monthly over 6 months [10], and a study in Senegal,
where SP-AQ was administered monthly for 5 months
(clinicaltrials.gov identifier: NCT01449045). These trials
have not resulted in changes in practice because the former
used an artemisinin-based combination for SMC, whereas
the latter occurred in an area where 4 months of SMC
would likely have been sufficient [11].
A second form of drug-based prevention that would be
easier for resource limited countries to implement would be
to treat malaria patients with long-acting artemisinin com-
bination therapies (LACTs), such as dihydroartemisinin-
piperaquine (DP) or artesunate-mefloquine (AS-MQ),
which protect children against further malaria episodes for
several weeks [12, 13]. The period of ‘post-treatment pro-
phylaxis’ after use of LACTs will be more useful in certain
epidemiological situations than in others, for example in
high burden areas where re-infection is likely soon after
treatment, and particularly in high burden seasonal settings
[14,15]. In such areas, LACTs could be used in combina-
tion with SMC, or instead of SMC where implementation
is not feasible, for example where the malaria transmission
season extends over a larger part of the year. Choice of
first-line antimalarial combination is not usually made with
consideration of malaria epidemiology, but this could be
rationalised if there was better evidence to show where it
would be effective.
To investigate these issues, we undertook a trial in the
Ashanti region of Ghana to estimate the protection
provided by SMC administered over 5 months and by a
long-acting ACT used for malaria case management. A
previous study in this area showed that amodiaquine-
artesunate administered every 2 months reduced fevers
presumptively treated as malaria by community-based
health workers (CHWs) by 37% (by intention to treat),
and by 61.5% in children who received all three courses
over the malaria transmission season [16]. However, the
previous study was unable to confirm all fevers as malar-
ia. CHWs resident in the study communities have since
been trained to use rapid diagnostic tests to confirm
malaria in children seeking treatment for illness following
a standard algorithm and provide treatment for malaria
using artemisinin-based combination therapies.
Methods
Study population and screening
The study, registered with ClinicalTrials.gov [NCT01651416],
was conducted among children aged 3–59 months living
in 13 communities in the Kwaso subdistrict, Ejisu-Juaben
municipality, in the Ashanti Region of Ghana (Figure 1).
The rainy season begins in May and lasts until October.
Malaria transmission lags around 1 month behind, with
transmission usually beginning to peak in June–July, and
lasting until November. Community sensitisation and
meetings with community leaders took place in early
2012 prior to the start of study activities. A census was
carried out in March 2012 to enumerate the children
under 5 years of age living in the area. Children were
screened in July 2012, and if eligible enrolled and fol-
lowed up for 12 months. Inclusion criteria were that the
child was aged 3–59 months; was a permanent resident
of one of the study communities and was able to take
and retain oral medication. Exclusion criteria were any
acute or chronic illness that needed further medical atten-
tion and any history of serious adverse reactions to drugs
used in the study. As in areas where SMC has now been
implemented, if a child was aged between 3 and
59 months at the time of enrolment, they could continue
to receive SMC that year even if subsequently older than
59 months.
Randomisation and allocation concealment
ID numbers comprising a four digit code and a check
digit were randomly allocated to one of three interven-
tion groups in a 1:1:1 ratio in permuted blocks of 12
using Stata version 13 (StataCorp, College Station, TX,
USA). Treatment allocation was held in opaque sealed
envelopes labelled only with the study ID number on the
front. Upon enrolment to the study, the next envelope in
the sequence was opened by the study team member to
determine the treatment allocation of the child to be used
throughout the study. This was carried out separately
from the screening process; individuals screening children
for eligibility were unaware of subsequent assignment.
The three randomisation groups were (i) placebo SMC,
plus a short-acting ACT (artemether-lumefantrine) for
treatment of malaria episodes (hereafter the ‘AL group’),
(ii) placebo SMC plus a long-acting ACT (dihy-
droartemisinin-piperaquine) for treatment of malaria
episodes (the ‘DP group’) and (iii) active SMC with
sulfadoxine-pyrimethamine plus amodiaquine, plus
artemether-lumefantrine for treatment of malaria
episodes (the ‘SMC group’).
Sample size
Incidence of malaria in the region between 16 and
24 months of age was estimated to be 1.4 per child-year
by active case detection [17]; we assumed passive case
detection via community-based health workers would
© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd 225
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detect 0.7 episodes per child-year. A study including
approximately 800 children in each group, allowing for a
10% loss to follow-up, would have 90% power to detect
a reduction of 20% in the malaria incidence rate between
children given a long-acting ACT and a short-acting
ACT. We assumed that SMC would reduce malaria inci-
dence by 60% during the peak in transmission and by
40% over the study period. A study with 800 children in
each group would have greater than 90% power to detect
a difference of 25% between children given a long-acting
ACT and those given SMC, and very high power to
detect larger differences between the SMC group and the
short-acting ACT.
Blinding
To facilitate community-based treatment of malaria with
the assigned regimen (artemether-lumefantrine or dihy-
droartemisinin-piperaquine), and to ensure that children
received the correct regimen if they attended at health
centres in the study area, ID cards were colour-coded
according to intervention group and labelled with the
regimen to be used for case management. The study was
therefore open-label with respect to the regimen used for
case management but blinded with respect to whether
seasonal malaria chemoprevention was active or placebo
(members of the research team from KNUST/CGHR and
LSHTM were aware of the allocation, but those who
administered the SMC, and mothers/children were
blinded).
Follow-up and interventions
The primary outcome was incidence of clinical malaria
detected passively by community health workers, and at
health centres serving the study area. If children pre-
sented with fever, history of fever or other symptoms sug-
gestive of malaria, no other obvious causes of fever, no
danger signs and tested positive for malaria by rapid
diagnostic test (RDT, First Response P. falciparum
HRP2/pLDH RDT (Premier Medical Corporation Ltd.,
Mumbai, India)), they received a full treatment course of
either artemether-lumefantrine (AL, Lumether, Kina-
pharma, Ghana) or dihydroartemisinin-piperaquine (DP,
Duo-Cotexcin, Holley Pharmaceuticals, China) according
to their intervention group. Children without symptoms
of malaria, or those who tested negative by RDT, were
referred to health centres or the hospitals serving the
area. CHWs and health centres serving the study commu-
nities were supplied with RDTs and stocks of both ACTs;
research staff stationed at health centres recorded illness
visits made by study children to the outpatient clinics.
Between July and November 2012, study children
received SMC with sulphadoxine-pyrimethamine plus
amodiaquine or identical placebos (Kinapharma, Ghana)
on five occasions (once per month). SP/SP placebo and the
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Figure 1 Location of the Ejisu-Juaben
District within the Ashanti Region of
Ghana.
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first dose of AQ/AQ placebo were given under observa-
tion, and the two remaining AQ/AQ placebo tablets were
administered by caregivers at home. Two age-based
dosages were used: children aged 1–4 years received 500/
25 mg S/P and 153 mg AQ; infants received half this dose
(250 mg/12.5 mg S/P, 76.5 mg AQ). In the days prior to
SMC delivery, community health workers and field super-
visors reminded mothers/caregivers that an SMC adminis-
tration was due to take place; announcements were also
made by local FM radio and by town criers. SMC or pla-
cebo was delivered by trained members of the study team
at a central point in each community. For the final two
cycles, community health workers followed up children
who did not receive the SMC from the central point to
administer the medicine. Children who reported illness or
fever at the time of SMC were screened with a rapid diag-
nostic test, and if positive treated with an ACT according
to their intervention group. Caregivers were followed up
by CHWs between 4 and 7 days after each SMC adminis-
tration to ask about adverse events and adherence to the
SMC regimen using a standard form.
Cross-sectional surveys
At enrolment, information was collected on basic demo-
graphic characteristics, household facilities (drinking
water source, toilet facilities, cooking fuel, roof construc-
tion and floor material), durable household assets and
ownership, age, condition and use of insecticide-treated
nets. Blood samples were taken for determination of hae-
moglobin and malaria parasitaemia. Haemoglobin was
measured using 301 HemocueTM analysers (HemoCue,
Angelholm, Sweden). Blood slides were prepared by
trained staff and double read at the laboratory of the
Centre for Global Health Research, Juaben, Ghana. Chil-
dren were also asked about any current symptoms of ill-
ness using a structured questionnaire.
Two further cross-sectional surveys were undertaken
after the period when SMC was administered (January
2013), and at the end of the study period (July 2013).
Blood samples were taken for determination of haemo-
globin and malaria parasitaemia, and children were asked
about any current illness symptoms.
Data management and statistical methods
All data were double entered and any discrepancies veri-
fied. Consistency and range checks were also undertaken
prior to locking the database for analysis, and linking
records with the randomisation code. All analyses were
undertaken in Stata version 13 (College Station, TX,
USA). A priori, we expected that the malaria incidence
would be highest in the AL group and lowest in the group
given SMC, with the group given DP for malaria case
management intermediate between these two (due to some
children benefiting from the longer period of post-treat-
ment prophylaxis after malaria episodes). The AL group
was therefore pre-specified as the reference group for
analyses. For the primary endpoint, the hazard ratio for
multiple episodes of malaria was estimated by Cox regres-
sion models. Robust standard errors (i.e. the Andersen-
Gill extension of the Cox model) were used to account for
clustering of failures within individuals; this estimates the
total effect of the intervention which is of primary public
health importance [18]. The Efron method was used for
tied failure times. Poisson regression with robust standard
errors was used to obtain the prevalence ratio of Plasmod-
ium falciparum parasitaemia and anaemia at the cross-
sectional surveys [19]. Linear regression models were used
to compare mean haemoglobin concentration. Covariates
pre-specified for inclusion in the analyses were age group,
sex, socio-economic status (SES), community of residence
and use of an insecticide-treated net (ITN).
Ethical approval
The study was approved by the ethics committees of the
London School of Hygiene and Tropical Medicine, UK,
the University of Leeds, UK and the Kwame Nkrumah
University of Science and Technology, Kumasi, Ghana.
Results
In July 2012, 2400 children were enrolled into the study
(Figure 2). A total of 23% were infants, and 51.3% were
male (Table 1). A community distribution of insecticide-
treated nets had occurred within the 6 months preceding
the baseline survey; most nets were therefore new and
insecticide treated, and 82.3% of children reported sleep-
ing under an insecticide-treated net the night before the
survey. Despite the large number of children randomised,
there were some imbalances between treatment groups at
baseline. The AL only group had fewer infants than other
groups (163, 20.4%); the SMC group had the largest
proportion of infants (203, 25.4%) and proportionally
fewer three-year-old children. Fewer SMC recipients used
ITN: 78.8% vs. 84.3% and 83.9% in the AL and DP
groups, respectively. Finally, there were some imbalances
between groups in the number of children recruited from
small communities (Table S1).
Malaria prevalence at baseline was 26.6% (95% CI
24.9%, 28.4%) and ranged from 13.3% to 57.6% in
different communities, with infection generally more
common in smaller communities (Figure S1). At baseline,
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50.5% of children were anaemic (Hb < 11 g/dl),
although most of this was mild, with only 4.98% of chil-
dren having Hb <8 g/dl. One child had Hb <5 g/dl. The
distribution of measured Hb was similar between the
three groups (Figure S2).
The lowest coverage of SMC occurred at the third
cycle of SMC, which was delivered by the study team at
a central point in each community (Table 2). Qualitative
research, to be reported separately, indicated that recent
efforts to promote diagnosis prior to treatment of malaria
in these communities may have reduced the perceived
importance of obtaining drugs for prevention in healthy
children. Access to the location where drugs were pro-
vided was identified as another important barrier, even
though the distances within each community to the
delivery point were small. In the fourth and fifth cycles,
children who did not attend were followed up at home
by community health workers, achieving higher coverage.
Overall around 40% of children received all five cycles of
SMC. Very few mothers reported adverse events to com-
munity health workers over the study period, although it
is likely that the capture of this is not complete. Reported
adherence to the three day course of SMC was very high:
close to 100% in all communities and exactly 100% in a
number of communities. However, it is unlikely that
adherence was in reality this high, as during the qualita-
tive component of this study, some caregivers were found
to have tablets remaining that had not been administered.
Cross-sectional surveys
At the end of the rainy season, prevalence of malaria
parasitaemia was lower in the SMC group than the AL
group, 12.4% vs. 20.3%: prevalence ratio 0.61 (95% CI:
3146
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Figure 2 CONSORT diagram.
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0.47, 0.80), P < 0.001. Prevalence was similar in the DP
and AL groups, 19.5% vs. 20.3%: PR 0.96 (95% CI:
0.76, 1.21), P = 0.727 (Table 3). Prevalence of para-
sitaemia with density ≥3000 per ll (prevalence ≥5000
per ll in parentheses) was similar in all three groups,
4.3% (3.4%), 4.2% (3.6%) and 4.7% (3.4%) in the
SMC, AL and DP groups, respectively. The distribution
of haemoglobin was very similar in all intervention
groups (Figure S2), and there were no differences in the
prevalence of anaemia. At the end of the study in July
2013, there were no differences in prevalence of para-
sitaemia (23.2%, 22.0%, 20.5% in the SMC, AL and
DP groups, respectively), or in the prevalence of anaemia
(Table 3). Illness symptoms were similar between the
study groups at both cross-sectional surveys (Tables S6
and S7).
Incidence of malaria
Malaria incidence over the study period is shown in Fig-
ure 3. Kaplan-Meier and Nelson-Aalen plots of malaria
incidence by randomisation group are shown in Figure 4.
During the period when SMC was administered, there
were 207 malaria episodes in 950.0 person-years of fol-
low-up. 157 children experienced a single episode of
malaria, 23 children experienced two episodes, and one
child in the AL group experienced four episodes. Relative
to the AL only group, the adjusted hazard ratio (aHR)
was 0.62 (95% CI: 0.41, 0.93), P = 0.020 in the SMC
group, a protective efficacy of 38.5% (95% CI 7.28%,
59.2%); the aHR was 1.18 (95% CI: 0.83, 1.67),
P = 0.356 in the DP group (Table 4). Among children
who received all five cycles of SMC or placebo, the aHR
Table 1 Baseline characteristics of study children by study group
Characteristic
AL group DP group SMC group
No. % No. % No. %
Age 0 163 20.4 184 23.0 203 25.4
1 217 27.1 222 27.8 208 26.0
2 157 19.6 128 16.0 149 18.6
3 149 18.6 152 19.0 127 15.9
4 114 14.2 114 14.2 113 14.1
Sex Female 382 47.8 402 50.2 386 48.3
Male 418 52.3 398 49.8 414 51.7
SES Lowest 150 20.2 148 19.7 151 20.2
Low 151 20.3 146 19.4 153 20.5
Average 158 21.2 160 21.3 148 19.8
High 145 19.5 152 20.2 140 18.7
Highest 140 18.8 146 19.4 156 20.9
Missing 56 48 52
Owns a net No 55 7.3 56 7.3 64 8.4
Yes 702 92.7 710 92.7 696 91.6
Missing 43 34 40
Net last night No 110 15.7 113 16.0 143 20.3
Yes 592 84.3 594 84.0 563 79.7
Missing 98 93 94
ITN last night No 110 15.7 114 16.1 150 21.2
Yes 592 84.3 593 83.9 556 78.8
Missing 98 93 94
Malaria parasitaemia No 569 71.8 583 73.7 587 74.6
Yes 223 28.2 208 26.3 200 25.4
Missing 8 9 13
Geometric mean
parasite density
952.8 (756.0, 1200.9) 972.4 (746.8, 1266.2) 930.1 (718.9, 1203.2)
Hb <5 g/dl 0 0 1 0.1 0 0
5–7.99 g/dl 34 4.5 38 4.9 41 5.4
8–10.99 g/dl 368 48.5 343 44.7 329 43.3
≥11 g/dl 357 47 386 50.3 390 51.3
Missing 41 32 40
Mean Hb (95% CI) 10.8 (10.7, 10.9) 10.9 (10.8,11.0) 10.9 (10.8, 11.0)
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in the SMC group relative to the AL only group was
0.53 (95% CI: 0.29, 0.95), a protective efficacy of 47.4%
(4.96%, 70.9%), P = 0.033. Although based on small
numbers, the mean interval between recurrent episodes
was greater in the DP group (n = 14 episodes, 64.1 days
in the DP group, vs. n = 8 episodes, 34.8 days in the AL
group and n = 4, 27.0 days in the SMC group,
P = 0.017 for DP vs. AL, P = 0.63 for SMC vs. AL).
During the post-SMC period, including the start of the
following transmission season in 2013, there were 135
episodes of malaria in 916.2 person-years of follow-up.
Relative to the AL only group, incidence of malaria
appeared higher in the SMC group and the DP group:
crude HRs 1.73 (95% CI: 1.00, 2.99), P = 0.050 and
1.70 (95% CI: 1.01, 2.86), P = 0.045, respectively. How-
ever, after adjusting for covariates (age, sex, SES, com-
munity and ITN use) aHRs were 1.36 (95% CI: 0.86,
2.14), P = 0.187 and 1.34 (95% CI: 0.86, 2.10),
P = 0.199, respectively.
Over the whole study period, including the SMC per-
iod, the dry season and the first few months of the 2013
transmission season, 2143 children never experienced
malaria, 198 children had one malaria episode, 40 chil-
dren experienced two episodes, and 13, 5 and 1 children
experienced 3, 4 and 5 episodes, respectively. Compared
to the AL only group, the aHR was 0.88 (95% CI 0.65,
1.20), P = 0.428 in the SMC group and 1.23 (95% CI
0.92, 1.65), P = 0.168 in the DP group. There was no
evidence of a difference in the interval between recurrent
episodes between groups over the whole study period.
Discussion
We investigated an extended programme of seasonal
malaria chemoprevention, and case management with a
long-acting ACT in an area of Ghana with a long rainy
season with two peaks. Strengths of this study are that a
relatively large cohort of children was monitored, the
interventions were successfully delivered, and it was pos-
sible to ensure a continuous supply of drugs and diagnos-
tic tests to community health workers who documented
malaria incidence. Limitations of this study are that not
all children were followed over the entire study period,
that randomisation did not achieve perfect balance in
factors known to be associated with malaria, that for
Table 2 Coverage of SMC/Placebo SMC courses administered,
by study group
AL group DP group SMC group
No. % No. % No. %
Coverage at each SMC round
Round 1 800 100 800 100 800 100
2 565 70.6 581 72.6 555 69.4
3 464 58.0 478 59.8 468 58.5
4 548 68.5 574 71.8 535 66.9
5 662 82.8 676 84.5 670 83.8
Number of SMC rounds received
1 54 6.8 44 5.5 50 6.3
2 96 12.0 80 10.0 82 10.3
3 133 16.6 131 16.4 149 18.6
4 191 23.9 213 26.6 228 28.5
5 326 40.8 332 41.5 291 36.4
At least 1 round 800 100 800 100 800 100
At least 2 rounds 746 93.3 756 94.5 750 93.8
At least 3 rounds 650 81.3 676 84.5 668 83.5
At least 4 rounds 517 64.6 545 68.1 519 64.9
5 rounds 326 40.8 332 41.5 291 36.4
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practical reasons it was necessary for the study to be
open-label with respect to the case-management regimen
and that coverage of the full complement of SMC cycles
was relatively low.
Malaria incidence was lower than expected: 196.4 per
1000 child-years over the study period in children who
received placebo SMC, compared to 700 per 1000 person-
years assumed in the sample size calculation. Several fac-
tors may have contributed to this. Firstly, due to a recent
distribution campaign, around 80% of children were regu-
larly sleeping under an insecticide-treated net. Secondly,
increased membership of Ghana’s National Health Insur-
ance scheme (allowing free treatment at health centres)
may have contributed to lower patronage of CHWs, as in a
recent study in Burkina Faso [20]. Thirdly, the practice of
CHWs referring children with a negative RDT result to
health facilities may have proved less popular with parents/
caregivers than presumptive treatment, as seen elsewhere
[21]. Staff were stationed at health centres to document
episodes that presented directly, but there may also have
been more use of the private sector when diagnostics were
introduced [22]. Due to the lower incidence of malaria, this
study was not adequately powered to evaluate robustly the
benefit of the longer period of post-treatment prophylaxis
provided by DP. During the SMC period, the interval
between episodes was longer in the DP group, but few chil-
dren experienced more than one episode, and this differ-
ence was not seen over the whole study period.
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Figure 4 Kaplan–Meier and Nelson–
Aalen plots of malaria incidence over the
study period. (a) Kaplan–Meier estimate
of the proportion of children remaining
free of malaria over the course of the
study period. (b) Nelson–Aalen estimate
of the cumulative Hazard over the study
period. Vertical black lines show the
approximate end of the SMC period (at
150 days) and the approximate start of
the 2013 transmission season (at
270 days).
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The protective efficacy of SMC was lower than
expected during the SMC period, at around 38%, with
no significant protection over the whole study period,
although this is partly diluted by the onset of the 2013
transmission season a few months before the study
ended. The lower efficacy may partly be due to rela-
tively low coverage of all five SMC cycles (36.4% in
the SMC group), but even among children who received
five cycles of SMC, protective efficacy was around 47%
during the SMC period, lower than the efficacy of 70-
80% seen in other studies of monthly SP-AQ [4, 6, 7],
or monthly artesunate-amodiaquine [10]. This could be
a chance finding, because malaria incidence was low
and confidence intervals for the efficacy are wide. How-
ever, if correct, it could suggest failure to complete the
3-day course of SMC (SP plus AQ on day one, AQ only
on days two and three): although SP alone retains rea-
sonably high efficacy in most of West Africa, the effi-
cacy of SP plus AQ is higher [5]. Adherence data were
collected but implausibly high values of adherence were
reported, as seen elsewhere [23]. Overall efficacy might
also be lower because incidence is relatively low in the
study area as a whole: 7 of the 13 study communities
have an annual incidence of malaria below 100 cases
per 1000 child-years at risk, the lower limit suggested
for SMC to be cost-effective [8]. In three small commu-
nities with a high prevalence of malaria at baseline and
high incidence during the transmission season (Korase,
Sarpeh and Timeabu) the protective efficacy of SMC
(any number of cycles) was more consistent with earlier
studies: 69.7% (95% CI: 22.7%, 88.1%). Potentially
supporting this is the fact that there was no benefit of
SMC on anaemia, in contrast to findings from SMC
studies in high transmission areas [6, 7] but agreeing
with areas of lower transmission [1].
Low efficacy may also be a consequence of the timing
of administration of the first cycle of SMC. At the baseline
survey in July, prevalence was around 26%, suggesting
that the transmission season was well underway by this
point. Although SP-AQ is likely to have very good cura-
tive efficacy in West Africa [24, 25], the benefit of SMC
will likely be greater where children are protected prior to
Table 4 Malaria incidence
Malaria
episodes Person-years
Incidence
rate*
Hazard ratio
(95% CI) P-value
Adjusted
hazard ratio (95% CI) P-value
SMC period
All children
AL group 72 314.0 229.3 [reference] – [reference] –
DP 90 318.9 282.2 1.23 (0.87, 1.73) 0.234 1.18 (0.83, 1.67) 0.356
SMC 45 317.2 141.9 0.62 (0.41, 0.92) 0.019 0.62 (0.41, 0.93) 0.020
Received five rounds
AL only 41 137.6 298.0 [reference] – [reference] –
DP 54 139.7 386.4 1.29 (0.82, 2.05) 0.274 1.16 (0.72, 1.87) 0.540
SMC 19 122.6 155.0 0.52 (0.29, 0.92) 0.026 0.53 (0.29, 0.95) 0.033
Post-SMC period
All children
AL only 31 309.6 100.1 [reference] – [reference] –
DP 52 305.2 170.4 1.70 (1.01, 2.86) 0.045 1.34 (0.86, 2.10) 0.199
SMC 52 301.4 172.5 1.73 (1.00, 2.99) 0.050 1.36 (0.86, 2.14) 0.187
Received five rounds
AL only 23 152.6 150.7 [reference] – [reference] –
DP 37 153.0 241.8 1.61 (0.87, 3.00) 0.131 1.22 (0.75, 1.98) 0.418
SMC 38 128.6 295.6 1.97 (1.04, 3.73) 0.038 1.44 (0.86, 2.42) 0.166
Whole study period
All children
AL only 103 623.6 165.2 [reference] – [reference] –
DP 142 624.1 227.5 1.37 (1.00, 1.88) 0.047 1.23 (0.92, 1.65) 0.168
SMC 97 618.5 156.8 0.95 (0.67, 1.33) 0.755 0.88 (0.65, 1.20) 0.428
Received five rounds
AL only 64 290.2 220.6 [reference] – [reference] –
DP 91 292.8 310.8 1.41 (0.93, 2.14) 0.108 1.20 (0.83, 1.74) 0.337
SMC 57 251.1 227.0 1.03 (0.65, 1.62) 0.913 0.91 (0.62, 1.35) 0.644
*Rate per 1000 person-years. SMC period: From date of receipt of first SMC or placebo course, until 1 month after the last SMC
course. Post-SMC period: from 1 month after last SMC course until the end of the study.
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exposure each year. If SMC was started too late in 2012
relative to the start of the transmission season, this sug-
gests that five cycles of SMC will be insufficient in this set-
ting, as there was also some malaria incidence in January
2013. Seven or possibly eight cycles could cover the per-
iod between May and January, but this raises new ques-
tions of cost-effectiveness, and the safety and acceptability
of a substantial additional number of SMC cycles.
Operationally, delivery of a larger number of SMC
cycles is more challenging, as the additional drugs needed
bring associated issues of cost, supply and storage. There
may also be more potential for campaign fatigue where
drugs are administered over a longer period, both on the
part of parents/caregivers and their children, and on the
part of delivery teams. This appeared to be the case here,
even in the context of a research study, with decreasing
coverage at the second and third cycles. However, the
increased coverage at the fourth and fifth cycles, achieved
by following up children at home, agrees with previ-
ous results showing that door-to-door delivery by
community-based health workers can achieve high SMC
coverage [26, 27] and underlines the need for close
supervision of SMC where it is delivered.
Conclusion
Five cycles of SMC administered during the peak of the
malaria transmission season reduced the burden of
malaria by around 50% during the rainy season.
Although this is lower than might be expected with
monthly SMC, and although the burden of malaria has
fallen compared to earlier studies undertaken in this area,
this still represents an important public health impact.
Lower efficacy may be partly attributable to use of other
protective measures and lower SMC coverage. It is also
likely that five monthly cycles of SMC were insufficient
to adequately address the full malaria transmission sea-
son and that an additional number of cycles would be
needed to achieve higher levels of protection using SMC
in this and similar areas. Further research is needed to
consider the role of SMC and other forms of chemopre-
vention in areas with seasonal malaria that extends over
6 or more months of the year.
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